GW Pharmaceuticals Plc (GWPH) News

GW Pharmaceuticals Plc (GWPH): $218.00

0.23 (+0.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GWPH News Items

GWPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GWPH News Highlights

  • GWPH's 30 day story count now stands at 18.
  • Over the past 25 days, the trend for GWPH's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • JAZZ, CGC and CURLF are the most mentioned tickers in articles about GWPH.

Latest GWPH News From Around the Web

Below are the latest news stories about Gw Pharmaceuticals Plc that investors may wish to consider to help them evaluate GWPH as an investment opportunity.

Healthcare Investors: Here's What You Need to Know About Medical Marijuana

Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.

Yahoo | April 11, 2021

Merck & Co. Is Flatlined But Watch For Its Revival

Photo by Sundry Photography/iStock Editorial via Getty Images Dependable and Familiar Make for Boring Profit is fiction for many of the hottest companies. Profit, once the vital factor for investors, is now passé. Merck & Co. (MRK) is a victim of its own success: Merck & Co is an old...

Harold Goldmeier on Seeking Alpha | April 8, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds TPCO, EGOV, GWPH, and CMD Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | April 7, 2021

Best Performing ETFs of Q1 2021

We highlight top performing ETF areas of the first quarter

Yahoo | April 6, 2021

The Benefits of Medical Marijuana, for Patients and Your Portfolio

Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.

Yahoo | April 5, 2021

Moore Kuehn Encourages GWPH, GNPK, PMBC, and SPFR Investors to Contact Law Firm

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: GW Pharmaceuticals plc (NASDAQ: GWPH) A proxy was recently filed with the SEC regarding Jazz Pharmaceuticals’ acquisition of GW Pharmaceuticals, which may omit material information regarding the financial metrics and analyses used to evaluate the merger. Under the proposed transaction, shareholders of GW Pharmaceuticals will receive $20.00 worth of shares of Jazz Pharmaceuticals and $200.0...

Yahoo | March 25, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRAH, JCS, GWPH, CRHM, EGOV; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | March 25, 2021

Why There Could Be at Least 1 More Big Acquisition in the Cannabis Industry This Year

There has been a surge of mergers and acquisitions activity in the cannabis industry of late. Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY) are linking up in one of the sector's highest-profile mergers, and other industries are getting in on the action. Jazz Pharmaceuticals (NASDAQ: JAZZ) is acquiring GW Pharmaceuticals (NASDAQ: GWPH), maker of Epidiolex, a cannabis-based seizure medication, for $7.2 billion, and a subsidiary of British American Tobacco is taking a 19.9% stake in OrganiGram.

Yahoo | March 24, 2021

GW Pharmaceuticals plc (NASDAQ:GWPH) Director Cabot Brown Sells 4,020 Shares

GW Pharmaceuticals plc (NASDAQ:GWPH) Director Cabot Brown sold 4,020 shares of the business’s stock in a transaction dated Thursday, March 18th. The shares were sold at an average price of $17.95, for a total transaction of $72,159.00. Following the completion of the sale, the director now owns 7,200 shares in the company, valued at $129,240. […]

Watchlist News | March 23, 2021

Samantha Gleit – Behind Debt Structure In Today's Cannabis Industry

Feuerstein Kulick LLP was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Navigating through the different complexities in the cannabis industry with limited liquidity sources and a state-by-state regulatory regime is time-consuming and can add an extra cost to a company’s structure. If a company doesn’t strategically plan ahead to address growth and capital needs, it can be detrimental in the increasingly competitive market. Thus, financial and legal planning is crucial in the evolving cannabis landscape, and having an experienced, reliable legal team can make or break a company...

Benzinga | March 23, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7593 seconds.